• 08 Jul 2025
• Admin
• News Article

Boston Scientific receives FDA approval for expanded labeling of FARAPULSE™ Pulsed Field Ablation System

Overview

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the instructions for use (IFU) labeling for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The updated labeling now includes approval for the system in the treatment of drug refractory, symptomatic persistent atrial fibrillation (AF), an arrythmia in which the heart beats abnormally for at least seven days.

About atrial fibrillation & current updates

•  AF affects an estimated 59 million people worldwide and many have the persistent form of the condition, which can cause dizziness, fatigue, shortness of breath and increase the risk of stroke. 
• The FARAPULSE PFA System treats AF by delivering pulsed field energy through a catheter to ablate heart tissue. 
• This approval updates the IFU for both the FARAWAVE™ PFA Catheter and the FARAWAVE NAV™ PFA Catheter to include treatment for patients with persistent AF.

Words from Brad Sutton: CMO, AF Solutions, Boston Scientific

""Backed by clinical evidence and our global commercial experience, this update advances our efforts to further shape the future of AF treatment with safe and effective ablation technologies,"" said Brad Sutton, M.D., chief medical officer, AF Solutions, Boston Scientific. ""We look forward to studying the system in new clinical trials, including patients in need of re-do ablations and those with more complex arrhythmias, which account for a large portion of the procedures today still using thermal ablation.""

The study beind approval

• The FDA approval for expanded labeling was supported by clinical evidence from phase one of the ADVANTAGE AF clinical trial presented at AF Symposium 2025 and recently published in the Journal of the American College of Cardiology and met both the primary safety and effectiveness endpoints. 
•  In the prospective, single-arm trial, 260 patients who were drug intolerant to at least one Class I/III anti-arrhythmic drug (AAD) were enrolled at 43 global sites. 
•  There were no reported incidences of stroke, pulmonary vein stenosis, atrio-esophageal fistula or major access complications and the symptomatic AF recurrence-free rate was 85.3%. 
• Observationally, among physicians that performed three or more procedures, the symptomatic recurrence-free rate increased to 91.4%.

Boston Scientific Launches ReMATCH Trial and Awaits Global Approvals

• Boston Scientific anticipates CE mark as well as approval in Japan and China in the coming months. 
• The company also recently initiated the ReMATCH IDE clinical trial, which will study approximately 375 patients across 40 centers in the U.S. and Asia. 
• The study will evaluate the safety and effectiveness of the FARAWAVE PFA Catheter for posterior wall ablation and pulmonary vein isolation in patients with persistent AF who previously received an ablation with a PFA, radiofrequency or cryoablation catheter and experienced a recurrence of the condition. 
• It will also evaluate adjunctive use of the FARAPOINT™ PFA Catheter* for cavotricuspid isthmus ablation and left atrial ablation of the mitral isthmus in the same patient population.

More information on the FARAPULSE PFA System is available here.

About Boston Scientific

• Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. 
• As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. 
• Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. 

Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.

Cautionary Statement Regarding Forward-Looking Statements

• This press release contains forward-looking statements within the meaning of:

Section 27A of the Securities Act of 1933
Section 21E of the Securities Exchange Act of 1934

• Forward-looking statements may be identified by words such as:

“anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” and similar terms.
These statements are based on our beliefs, assumptions, and estimates using currently available information and are not guarantees of future performance or outcomes.

• Forward-looking statements include, but are not limited to:

Business plans and strategies
Product performance and impact
Clinical trial progress
Anticipated product approvals and launches

• If assumptions prove incorrect or risks materialize, actual results may differ materially from the projections.
• Risks and uncertainties that could affect outcomes include:

- Economic conditions, including foreign currency fluctuations
- U.S. and global political, regulatory, reimbursement, and competitive environments
- Geopolitical events
- Manufacturing, distribution, and supply chain disruptions and cost increases
- Cybersecurity events
-Public health emergencies or climate-related extreme weather
- Labor shortages and rising labor costs
- Variability in outcomes of clinical trials and market studies
-New product launches and expected procedural volumes
-Acquisition closings and integrations
-Demographic trends
- Intellectual property matters and litigation
- Financial market conditions
- Execution and effect of our cost-savings and growth strategies
- Business decisions made by the company or its competitors

• Many of these factors are difficult or impossible to predict and are often outside of our control.
• For a detailed list of risks, refer to:

Part I, Item 1A – Risk Factors in our latest Annual Report on Form 10-K
Updates in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q

• We disclaim any obligation to publicly update or revise any forward-looking statements, unless legally required.
• This cautionary statement applies to all forward-looking statements contained in this document.